1995年起在南京鼓楼医院从事血液病临床工

1、十三五江苏省科教强卫医学领军人才与创新团队

项目来源：江苏省卫计委；项目起止时间：2017-01至2021-12 ；

项目主持人：陈兵；经费金额：300万




2、CARgy3-T细胞治疗B细胞淋巴瘤临床前研究

项目来源：江苏省科技计划项目临床前沿；项目起止时间：2017-09至2020-12；

项目主持人：陈兵；经费金额：200万

1、Doxorubicin-Loaded PEG-CdTe Quantum Dots as a Smart Drug Delivery System for Extramedullary Multiple Myeloma Treatment. Nanoscale Res Lett .

2018-11.13(1):373.




2、Pre-treatment red blood cell distribution width provides prognostic information in multiple myeloma.Clin Chim Acta .2018-0613(1):e0191955.




3、Expression of MAGEC1/CT7 provides prognostic information in multiple myeloma.Leukemia & lymphoma .2017-01.58(1):244-246.




4、Silencing MAGE-C1/CT7 enhances the anticancer effects of bortezomib in multiple myeloma cell line Int J Clin Exp Med .2016-08.9(8):15124-15134.




5、A new strategy for TiO2 whiskers mediated multi-mode cancer treatment. Nanoscale Res Lett. 2015-02.10: 94.




6、PEG–PLGA–PLL nanoparticles in combination with gambogic acid for reversing multidrug resistance of K562/A02 cells to daunorubicin. RSC Advances. 2015-06.

5-61051.




7、Anti-CD22-conjugated CdTe QDs co-loaded with doxorubicin and gambogic acid: A novel

platform for lymphoma treatment .RSC advances .2017-07.7(54):33905-33913.




8、Prognostic relevance of protein expression,clinical factors, and MYD88 mutation in

primary bone lymphoma Oncotarget.2017-08.8 ( 39):65609-65619.




9、Doxorubicin-loaded platelets conjugated with anti-CD22 mAbs: a novel targeted delivery system for lymphoma treatment with cardiopulmonary avoidance. Oncotarget

2017-08.8(35):58322-58337.




10、Comparison of outcomes in hematological malignancies treated with haploidentical or HLA-identical sibling hematopoietic stem cell transplantation following myeloablative conditioning: A metaanalysis. PLoS One .2018-01.13(1):e01919 55.




11、TP53 mutation predicts the poor prognosis of non-Hodgkin lymphomas: Evidence

from a meta-analysis .PLoS One.2017-04.12(4):e0174809.




12、STAT5 gene polymorphisms are associated with the response of acute myeloid leukemia

patients to Ara-C-based chemotherapy.Leukemia & lymphoma.2016-04.57-4-921.




13、Characteristics and mutation analysis of Phpositive leukemia patients with T315I

mutation receiving tyrosine kinase inhibitors. OncoTargets and Therapy.2017-09.10

:4731-4738.




14、A case report and literature review of primary resistant Hodgkin lymphoma: a

response to anti-PD-1 after failure of autologous stem cell transplantation and

brentuximab vedotin. OncoTargets and therapy.2016-09.9: 5781.




15、Primary Philadelphia chromosome positive acute myeloid leukemia: A case repor

.Medicine (Baltimore).2018-11.97(44):e12949.




16、Composite primary breast diffuse large Bcell lymphoma and T lymphoblastic

leukemia/lymphoma: report of a case and review of literature. Int J Clin Exp Pathol.

2015-08.8-8-9629.




17、An Effective Gene Selection Method for Cancer Subtype Classification Based on

Predatory Search Genetic Algorithm and Support Vector Machine. Journal of Computational and Theoretical Nanoscience. Journal of Computational and Theoretical Nanoscience.

2015-09.1(11);1-7.




18、Splenic diffuse red pulp small B-cell lymphoma in an Asian female patient with review of literature. Int J Clin Exp Med .2018-01.9(3):3993-3998.




19、Acute lymphoblastic leukemia in a patient with IgG4-related disease. Pharmazi

Pharmazie.2018-07.73(7):418-421.




20、The association between expression of hypoxia inducible factor-1a and multi-drug resistance of acute myeloid leukemia Translational Cancer Research.2017-02.6(1):

198-205.




21、The polymorphism of JAK2 rs56118985 may be a predictive marker of the treatment

responses of acute myeloid leukemia patients .Translational Cancer Research.2017-05.10:4731-4738.




22、Secondary Epstein-Barr virus-associated angioimmunoblastic Tcell lymphoma in a

patient with diffuse large B-cell lymphoma: report of a case and review of literature.

Translational Cancer Research.2017-02.10(1):1693-1708